Zeposia is owned by Celgene Intl.
Zeposia contains Ozanimod Hydrochloride.
Zeposia has a total of 4 drug patents out of which 0 drug patents have expired.
Zeposia was authorised for market use on 25 March, 2020.
Zeposia is available in capsule;oral dosage forms.
Zeposia can be used as treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, indicated for the treatment of moderately to severely active ulcerative colitis.
Drug patent challenges can be filed against Zeposia from March, 2024.
The generics of Zeposia are possible to be released after 15 November, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8481573 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
US8796318 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9382217 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
US10239846 | CELGENE INTL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | May 27, 2024 |
New Chemical Entity Exclusivity (NCE) | Mar 25, 2025 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: March, 2024
Market Authorisation Date: 25 March, 2020
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the treatment of moderately to severely active ulcerative colitis
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic